Arrowhead Pharmaceuticals (ARWR) Return on Capital Employed (2011 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Return on Capital Employed came in at 13.52% in Q1 2026, down 247.0% YoY from 9.2% in Q1 2025, and down 151.62% on a QoQ basis from 26.2% in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Return on Capital Employed (2011 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 16 years of Return on Capital Employed data on file, last reported at 13.52% in Q1 2026.
- Quarterly Return on Capital Employed fell 247.0% year-over-year to 13.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.52% (down 247.0% YoY) and the FY2025 annual result came in at 9.22%, up 7997.0% from the prior year.
- Return on Capital Employed eased to 13.52% in Q1 2026, from 26.2% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 26.2% in Q4 2025 to a low of 66.51% in Q2 2024.
- A 5-year average of 28.41% and a median of 23.49% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed slumped 4656 bps — and 2025, when it surged 8988 bps.
- Tracing ARWR's Return on Capital Employed over 5 years: stood at 23.49% in 2022, then slumped by 102 bps to 47.36% in 2023, then sank by 34 bps to 63.68% in 2024, then soared by 141 bps to 26.2% in 2025, then slumped by 152 bps to 13.52% in 2026.
- The last three Return on Capital Employed figures came in at 13.52% (Q1 2026), 26.2% (Q4 2025), and 8.28% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | -11.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.88% |
| Mar 31, 2026 | -13.52% |
| Dec 31, 2025 | 26.20% |
| Sep 30, 2025 | 8.28% |
| Jun 30, 2025 | -8.42% |
| Mar 31, 2025 | -11.05% |
| Dec 31, 2024 | -63.68% |
| Sep 30, 2024 | -66.15% |
| Jun 30, 2024 | -66.51% |
| Mar 31, 2024 | -65.30% |
| Dec 31, 2023 | -47.36% |
| Sep 30, 2023 | -30.36% |
| Jun 30, 2023 | -23.34% |
| Mar 31, 2023 | -18.74% |
| Dec 31, 2022 | -23.49% |
| Sep 30, 2022 | -30.62% |
| Jun 30, 2022 | -26.62% |
| Mar 31, 2022 | -22.27% |
| Dec 31, 2021 | -35.05% |
| Sep 30, 2021 | -25.87% |